Haemophilia. Hereditary factor VIII deficiency
Conditions
Interventions
Intervention 1: Intervention group1:
patients based on the belief treatment & based on previous history (questionnaire available) are divided into consumer Aryo (Group A),
two bleeding event in ea
Treatment - Drugs
Intervention group1:
patients based on the belief treatment & based on previous history (questionnaire available) are divided into consumer Aryo (Group A),
two bleeding event in each category wi
Intervention group 2:
Patient care based on the belief & treatment history (according to the questionnaire) will be divided into consumer Faiba (Group F): 2 bleeding event in each category will be d
Control group:
because of consistency of study the patients are divided into control group(O) Indifferent or new
Sponsors
Aryogen biopharma co.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with severe hemophilia a with high inhibitor titers (greater than or equal to 5 Bethesda) in pilot studies to assess the attitude of coagulation shortcuts are classified. Exclusion criteria: patients who have previously unclassified; patients with coagulation problems, developed liver problems; patients who received coagulation products is over 5 days ago and patients who have bleeding arthritis in the joint within 7 days ago.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: 1, 3, 6, 9 and 12 hours after intervention. Method of measurement: Measure kavakli.;Range of motion. Timepoint: 1, 3, 6, 9 and 12 hours after intervention. Method of measurement: Measure kavakli. | — |
Secondary
| Measure | Time frame |
|---|---|
| Bleeding control. Timepoint: 24 hours. Method of measurement: Evaluation of treatment success. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMina Golestani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed